AbbVie Inc. $ABBV Shares Sold by Highland Capital Management LLC

Key Points

• Highland Capital cut its stake in AbbVie by 12.2%, selling 5,703 shares and leaving 41,131 shares valued at about $9.523 million at the end of the quarter.
• Q3 results beat expectations with EPS of $1.86 vs. $1.77 and revenue of $15.78 billion (+9.1% YoY), and AbbVie set Q4 2025 EPS guidance at 3.320–3.360 (analysts forecast ~12.31 EPS for the year).
• AbbVie raised its quarterly dividend to $1.73 (from $1.64), an annualized $6.92 and ~3.0% yield; the ex-dividend date is Jan 16 and the payment is Feb 17.

Highland Capital Management LLC lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 12.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,131 shares of the company's stock after selling 5,703 shares during the period. Highland Capital Management LLC's holdings in AbbVie were worth $9,523,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. Marshall & Sullivan Inc. WA purchased a new stake in shares of AbbVie in the second quarter valued at approximately $25,000. Evolution Wealth Management Inc. purchased a new position in AbbVie during the second quarter worth approximately $26,000. TD Capital Management LLC boosted its stake in AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company's stock worth $27,000 after buying an additional 58 shares during the last quarter. Spurstone Advisory Services LLC purchased a new stake in AbbVie in the 2nd quarter valued at $28,000. Finally, Financial Gravity Companies Inc. purchased a new stake in AbbVie in the 2nd quarter valued at $36,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Price Performance

Shares of ABBV opened at $230.07 on Friday. The firm has a 50-day simple moving average of $226.73 and a two-hundred day simple moving average of $212.41. The stock has a market cap of $406.63 billion, a PE ratio of 174.30, a P/E/G ratio of 1.31 and a beta of 0.36. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period in the prior year, the business posted $3.00 EPS. The business's revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This is an increase from AbbVie's previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Friday, January 16th. AbbVie's dividend payout ratio (DPR) is 496.97%.

Wall Street Analyst Weigh In

ABBV has been the topic of several analyst reports. Berenberg Bank upgraded AbbVie from a "hold" rating to a "buy" rating and lifted their price target for the stock from $170.00 to $270.00 in a report on Wednesday, September 17th. Weiss Ratings restated a "hold (c)" rating on shares of AbbVie in a research report on Wednesday, October 8th. Morgan Stanley boosted their target price on shares of AbbVie from $261.00 to $269.00 and gave the company an "overweight" rating in a report on Friday, December 12th. Scotiabank initiated coverage on shares of AbbVie in a research note on Thursday, November 13th. They issued a "sector outperform" rating and a $280.00 price target for the company. Finally, UBS Group raised their price target on shares of AbbVie from $195.00 to $220.00 and gave the stock a "neutral" rating in a report on Friday, November 7th. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, AbbVie has a consensus rating of "Moderate Buy" and a consensus price target of $245.84.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.